

lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. *Int J Clin Oncol.* in press.

14. Itamochi H, Kato M, Nishimura M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T. : Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. *Hum Cell.* 25:111-5.2012.

(研究分担者：板持広明)

1. Deura I, Shimada M, Hirashita K, Sugimura M, Sato S, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J: Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy. *Int J Clin Oncol.* in press.
2. Naniwa J, Itamochi H, Horie Y, Kudoh A, Sato S, Sato S, Shimada M, Oishi T, Kigawa J, Harada T: Recurrent spontaneous pneumothorax following chemotherapy in a patient with ovarian granulosa cell tumor: a case report. *Int Canc Conf J.* in press.
3. Sato S, Itamochi H: DNA repair and chemotherapy. INTECH, Rijeka. in

press.

4. Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzazanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A: Gynecologic Cancer InterGroup (GCIg) consensus review for clear cell carcinoma of the ovary. *Int J Gynecol Cancer.* 24: S20-S25, 2014.
5. Miyata K, Yotsumoto F, Nam SO, Odawara T, Manabe S, Ishikawa T, Itamochi H, Kigawa J, Takada S, Asahara H, Kuroki M, Miyamoto S: Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma. *Cancer Med.* 3: 1159-1169, 2014.
6. Sato S, Itamochi H: Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. *Ther Adv Med Oncol.* 6: 293-304, 2014.
7. Takeshima N, Matoda M, Abe M, Hirashima Y, Kai K, Nasu K, Takano M, Furuya K, Sato S, Itamochi H, Tsubamoto H, Hasegawa K, Terao K, Otsuki T, Kuritani K, Ito K: Efficacy and safety of triple therapy with aprepitant, palonosetron, and

- dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. *Support Care Cancer*. 22: 2891-2898, 2014.
8. Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T: The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. *Oncol Rep*. 32: 553-558, 2014.
 9. Uegaki K, Shimada M, Sato S, Deura I, Naniwa J, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J: Outcome of stage IB2–IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. *Int J Clin Oncol*. 19: 348-353, 2014.
 10. Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T: Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary. *Int J Gynecol Cancer*. 24: 444-453, 2014.
 11. Itamochi H, Nishimura M, Oumi N, Kato M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, Kigawa J, Harada T: Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. *Int J Gynecol Cancer*. 24: 61-69, 2014.
 12. Tuna M, Itamochi H: Insulin-like growth factor I regulates the expression of isoforms of Wilms' tumor 1 gene in breast cancer. *Tumori*. 99: 715-722, 2013.
 13. Taniguchi F, Itamochi H, Harada T, Terakawa N: Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary. *Int J Gynecol Cancer* 23: 791-796, 2013
 14. Itamochi H, Kato M, Nishimura M, Oumi N, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T: Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. *Hum Cell* 26: 121-127, 2013
 15. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Takano M, Ushijima K, Tanyi JL, Coukos

- G, Lu Y, Mills GB, Verhaak RG: Predicting time to ovarian carcinoma recurrence using protein markers. *J Clin Invest* 123: 3740-3750, 2013
16. Shimada M, Itamochi H, Kigawa J: Nedaplatin: a cisplatin derivative in cancer chemotherapy. *Cancer Manage Res* 2013: 67-76, 2013
 17. Naniwa J, Itamochi H, Kigawa J: Implication of Clear Cell and Mucinous Histology. In: *Ovarian Cancer - A Clinical and Translational Update*, Díaz-Padilla I ed., INTECH, Rijeka, pp. 97-116, 2013
 18. Itamochi H, Kigawa J: Clinical trials and future potential of targeted therapy for ovarian cancer. *Int J Clin Oncol* 17: 430-440, 2012 (査読あり)
 19. Sato S, Fujiwara H, Oishi T, Shimada M, Machida S, Takei Y, Itamochi H, Suzuki M, Kigawa J: Evaluation of a formula for individual dosage of nedaplatin based on renal function. *Cancer Chemother Pharmacol* 69: 599-603, 2012
 20. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K: for The Japanese Serous Ovarian Cancer Study Group: High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway. *Clin Cancer Res* 18: 1374-1385, 2012
 21. Minagawa Y, Shimada M, Itamochi H, Sato S, Sato S, Okada M, Kitada F, Kigawa J: Feasibility study on biweekly Paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma. *Gynecol Obstet Invest.* 73: 272-276, 2012
 22. Shimada M, Fujiwara H, Sato S, Oishi T, Itamochi H, Machida S, Takei Y, Harada T, Suzuki M, Kigawa J: Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. *Cancer Chemother Pharmacol* 70: 33-38, 2012
 23. Nonaka M, Itamochi H,

- Kawaguchi W, Kudoh A, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T: Activation of the Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Overcomes Cisplatin Resistance in Ovarian Carcinoma Cells. *Int J Gynecol Cancer* 22: 922-929, 2012
24. Itamochi H, Kato M, Nishimura M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T: Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. *Hum Cell* 25: 111-115, 2012
25. Sato S, Itamochi H: Bevacizumab and ovarian cancer. *Curr Opin Obstet Gynecol* 24: 8-13, 2012
- (研究分担者：笠松高弘)
1. Eto T, Saito T, Shimokawa M, Hatae M, Takeshima N, Kobayashi H, Kasamatsu T, Yoshikawa H, Kamura T, Konishi I. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: A retrospective multi-institutional study of 426 patients in Japan. *Gynecol Oncol* 12013.
2. Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T, Japan Clinical Oncology G. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). *Br J Cancer* 12013;108: 1957-63.
3. Matsubara A, Sekine S, Ogawa R, Yoshida M, Kasamatsu T, Tsuda H, Kanai Y. Lobular Endocervical Glandular Hyperplasia Is a Neoplastic Entity With Frequent Activating GNAS Mutations. *Am J Surg Pathol* 12013.
4. Murakami N, Kasamatsu T, Morota M, Sumi M, Inaba K, Ito Y, Itami J. Radiation Therapy for Stage IVA Cervical Cancer. *Anticancer Res* 12013;33: 4989-94.

5. Murakami N, Kasamatsu T, Sumi M, Yoshimura R, Takahashi K, Inaba K, Morota M, Mayahara H, Ito Y, Itami J. Radiation therapy for primary vaginal carcinoma. *J Radiat Res* 2013;54: 931-7.
6. Koga Y, Katayose S, Onda N, Kasamatsu T, Kato T, Ikeda S, Ishikawa M, Ishitani K, Hirai Y, Matsui H. Usefulness of Immuno-Magnetic Beads Conjugated with Anti-EpCAM Antibody for Detecting Endometrial Cancer Cells. *Journal of Cancer Therapy* 4:1273-82, 2013.
7. Uehara T, Onda T, Togami S, Amano T, Tanikawa M, Sawada M, Ikeda S, Kato T, Kasamatsu T. Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma. *Int J Gynecol Cancer* 2012;22: 280-5.
8. Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. *Cancer Sci* 2012;103: 926-32.
9. Togami S, Kasamatsu T, Sasajima Y, Onda T, Ishikawa M, Ikeda S, Kato T, Tsuda H. Serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature. *Gynecol Obstet Invest* 2012;73: 26-31.
10. Kuroda Y, Murakami N, Morota M, Sekii S, Takahashi K, Inaba K, Mayahara H, Ito Y, Yoshimura R, Sumi M, Kagami Y, Katsumata N, Kasamatsu T, Itami J. Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. *J Radiat Res* 2012;53: 588-93.
11. Ikeda S, Yoshimura K, Onda T, Kasamatsu T, Kato T, Ishikawa M, Sasajima Y, Tsuda H. Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix. *J Obstet Gynaecol Res* 2012;38: 1260-5.
12. Eto T, Saito T, Kasamatsu T, Nakanishi T, Yokota H, Satoh T, Nogawa T, Yoshikawa H, Kamura T, Konishi I. Clinicopathological prognostic

factors and the role of cytoreduction in surgical stage IVb endometrial cancer: A retrospective multi-institutional analysis of 248 patients in Japan. *Gynecol Oncol* 2012;127: 338-44.

(研究分担者：石川光也)

1. Togami S, Sasajima Y, Kasamatsu T, Oda-Otomo R, Okada S, Ishikawa M, Ikeda SI, Kato T, Tsuda H. Immunophenotype and Human Papillomavirus Status of Serous Adenocarcinoma of the Uterine Cervix. *Pathol Oncol Res*. Published online: 05 November 2014.

(研究分担者：波多江正紀)

1. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: A retrospective multi-institutional study of 426 patients in Japan. Eto T, Saito T, Shimokawa M, Hatae M, Takeshima N, Kobayashi H, Kasamatsu T, Yoshikawa H, Kamura T, Konishi I. *Gynecol Oncol*. 2013 Dec;131(3):574-80
2. Predicting time to ovarian carcinoma recurrence using protein markers. Yang JY,

Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. *J Clin Invest*. 2013 Sep 3;123(9):3740-50

3. Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study. Liao SY, Rodgers WH, Kauderer J, Darcy KM, Carter R, Susumu N, Nagao S, Walker JL, Hatae M, Stanbridge EJ. *Br J Cancer*. 2013 Feb 19;108(3):613-20.
4. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T,

- Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M,
5. 卵巣癌初回化学療法の変遷 波多江正紀, 中村俊昭, 川畑宜代, 宮島千草, 松本純, 田平達則, 荒木梢, 富永美沙, 山本文子 鹿児島市立病院産婦人科 産科と婦人科 79(6): 701-707, 2012.
 6. 腹腔鏡下に性腺を摘出した精巢性女性化症候群の一例 中村俊昭, 川畑宜代, 山本文子, 波多江正紀 鹿児島市立病院産婦人科 日本産科婦人科内視鏡学会雑誌 28(1): 313-313, 2012.

(研究分担者:道前洋史)

1. Emura T, Konno Y, Michimae H. Statistical Inference Based on the Nonparametric Maximum Likelihood Estimator under Double-truncation. Lifetime Data Analysis, in press.
2. Emura T, Kao F and Michimae H. An improved nonparametric estimator of distribution function for censored bivariate competing risk models. Journal of Multivariate Analysis, 132: 229-241, 2014.
3. Niho S, Suzuki K, Sakai H, Kaburagi T, Koike T, Minato K, Kato T, Okamoto H, Seto T, Hosomi Y, Shimizu K, Oshita F, Kunitoh H, Tsuboi M, Michimae H, Takeuchi M, Watanabe K and Ikeda N. Feasibility trial of adjuvant chemotherapy with docetaxel plus cisplatin followed by

maintenance chemotherapy of S-1 in completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809. British Journal of Cancer, 109(3):545-551, 2013.

4. Katumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Komada S, Terauchi F, Tsuda H, Sugiyama T and Ochiai K. Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. The Lancet Oncology, 14(10):1020-1026, 2013.

(研究分担者:落合和徳)

1. 落合和徳.【婦人科がんの予防戦略と早期診断】 卵巣がん リスク因子を考慮した卵巣がん予防. 臨床婦人科産科 2013;67(8):825-831.
2. 白石絵莉子, 山本瑠伊, 山下修位, 林 千景, 駒崎裕美, 高橋一彰, 堀谷まどか, 永田知映, 上田 和, 斉藤元章, 矢内原 臨, 高倉 聡, 山田恭輔, 落合和徳, 岡本愛光. 卵巣原発ミューラー管性腺肉腫の1例 妊孕性温存手術後の再発. 東京産科婦人科学会 雑誌;62(1):116-121,2013
3. 飯田泰志, 田部 宏, 落合和徳.【次

- 世代の婦人科がん治療を展望する】
婦人科がんに対する分子標的薬の
開発:JGOG 臨床試験. 産婦人科の
実際;62(3):283-288,2013
4. 落合和徳. 化学療法先行治療を進行
卵巣がんの標準治療とするため
の研究 卵巣明細胞腺癌における
IL-6 シグナルに関する検討 分担
研究報告書. 厚生労働科学研究費
補助金(がん臨床研究事業)(H22-
がん臨床-一般-020)平成 24 年度総
括研究報告書;37-8,2013
 5. Yamada K, Tanabe H, Imai M, Jobo T,
Kudo K, Fujiwara H, Nagata C,
Furuya K, Suzuki M, Ochiai K,
Tanaka T, Yasuda M. Feasibility study
of paclitaxel plus carboplatin in
patients with endometrial cancer: a
Japan Kanto Tumor Board study
(JKTB trial). *J Obstet Gynaecol
Res*;39(1):311-6,2013
 6. Ushijima K, Kamura T, Tamura K,
Kuzuya K, Sugiyama T, Noda K,
Ochiai K. Docetaxel/irinotecan
combination chemotherapy in
platinum/taxane-refractory
and-resistant ovarian
cancer:JGOG/WJGOG Intergroup
Study. *Int J Clin
Oncol.*;18(1):126-31,2013
 7. 岡本愛光, 田部 宏, 落合和徳, 田
中忠夫. 【卵巣癌治療の変遷と今後の
展開】卵巣癌の最近の臨床試験
の動向について-GCIG 会議より. 産
科と婦人科;79(6):767-73,2012
 8. 高倉 聡, 落合和徳. 【婦人科がん-
最新の研究動向】婦人科がん-概論-
国内共同研究の動向. *日本
臨*;70(増刊号 4):52-8,2012
 9. 矢内原 臨, 落合和徳. 【婦人科が
ん-最新の研究動向】卵巣がん卵巣
癌の治療 治療概論. *日本臨
床*;70(増刊号 4):557-9, 2012
 10. 永田知映, 落合和徳. 【婦人科悪
性腫瘍の診断治療アップデート】卵
巣がん 妊孕性温存手術. 産婦人
科の実際;61(3):425-31, 2012
 11. 落合和徳. 上皮性卵巣癌における
免疫関連遺伝子の発現解析. 厚生
労働科学研究費補助金(がん臨床
研究事業) 分担研究報告
書;33-5,2012
- (研究分担者: 岡本愛光)
1. Hirata Y, Murai N, Yanaihara N,
Saito M, Saito M, Urashima M,
Murakami Y, Matsufuji S, Okamoto
A. MicroRNA-21 is a candidate
driver gene for 17q23-25
amplification in ovarian clear cell
carcinoma. *BMC Cancer*. 2014 Nov
3;14(1):799. doi:
10.1186/1471-2407-14-799.
 2. Okamoto A, Glasspool RM,
Mabuchi S, Matsumura N, Nomura
H, Itamochi H, Takano M, Takano T,
Susumu N, Aoki D, Konishi I,
Covens A, Ledermann J,
Mezzazanica D, Steer C, Millan D,
McNeish IA, Pfisterer J, Kang S,
Gladieff L, Bryce J, Oza
A. Gynecologic Cancer InterGroup

- (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary. *Int J Gynecol Cancer*. 2014 Nov;24(9 Suppl 3):S20-5.
3. Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, Nagata C, Yanaihara N, Tanabe H, Okamoto A. Impact of Surgical Staging in Stage I Clear Cell Adenocarcinoma of the Ovary. *Int J Gynecol Cancer*. 2014 Sep;24(7):1181-9.
 4. Seki T, Yanaihara N, Hirata Y, Fukunaga M, Tanaka T, Okamoto A. Uterine endometrial carcinoma with trophoblastic differentiation: a case report with literature review. *Eur J Gynaecol Oncol*. 2014;35(4):461-4.
 5. Saitou M, Iida Y, Komazaki H, Narui C, Matsuno K, Kawabata A, Ueda K, Tanabe H, Takakura S, Isonishi S, Sasaki H, Okamoto A. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer. *Arch Gynecol Obstet*. 2014 Sep 4. [Epub ahead of print]
 6. Kajiwara K, Kimura E, Nakano M, Takano H, Okamoto A. Clinical experience of J-VAC drain for skin closure in the laparotomy of obstetrics and gynecology. *J Obstet Gynaecol Res*. 2014 Apr;40(4):1089-97.
 7. 梶原 一紘(東京慈恵会医科大学産婦人科), 和田 誠司, 堀谷 まどか, 土橋 麻美子, 田中 邦治, 種元 智洋, 大浦 訓章, 岡本 愛光. 胎児死亡となった先天性 QT 延長症候群の 1 例(原著論文) 日本周産期・新生児医学会雑誌(1348-964X)49 巻 3 号 Page1115-1120(2013.09)
 8. Shimizu A, Kobayashi N, Shimada K, Oura K, Tanaka T, Okamoto A, Kondo K. Novel gene therapy viral vector using non-oncogenic lymphotropic herpesvirus. *PLoS One*. 2013;8(2):e56027.
 9. Koyama-Nasu R, Takahashi R, Yanagida S, Nasu-Nishimura Y, Oyama M, Kozuka-Hata H, Haruta R, Manabe E, Hoshino-Okubo A, Omi H, Yanaihara N, Okamoto A, Tanaka T, Akiyama T. The Cancer Stem Cell Marker CD133 Interacts with Plakoglobin and Controls Desmoglein-2 Protein Levels. *PLoS One*. 2013;8(1):e53710.
 10. 舟木 哲(東京慈恵会医科大学産婦人科講座), 梶原 一紘, 大浦 訓章, 佐藤 泰輔, 野口 幸子, 佐藤 陽一, 堀谷 まどか, 土橋 麻美子, 田中 邦治, 川口 里恵, 種元 智洋, 恩田 威一, 岡本 愛光. 頸管妊娠に対し子宮動脈塞栓術施行後次回妊娠で分娩後大量出血をきたし再度子宮動脈塞栓術を施行した 1 例(原著論文/症例報告) 東京産科婦人科学会会誌(2186-0599)62 巻 3 号 Page450-455(2013.07)

11. 佐藤 安南(国立成育医療研究センター 周産期センター産科),梅原 永能,廣瀬 宗,山村 倫啓,上出 泰山,和田 誠司,渡辺 典芳,塚原 優己,久保 隆彦,北川 道弘,左合 治彦,和田 誠司,岡本 愛光. 帝王切開癒痕部妊娠において異なる転帰をたどった2例(原著論文) 東京産科婦人科学会会誌(2186-0599)62 卷 2 号 Page309-313(2013.04)
12. 石橋 由朗(東京慈恵会医科大学 附属病院 手術部),三澤 健之,小村 伸朗,大熊 誠尚,芦塚 修一,尾高 真,杉本 公平,山田 祐紀,柏木 秀幸,森川 利昭,矢永 勝彦,岡本 愛光,潁川 晋,森山 寛. 【各科におけるトレーニングシステムの構築】学内技術認定制度と連携した研修医からの内視鏡外科手術教育(解説/特集) 日本外科系連合学会誌(0385-7883)38 卷 2 号 Page235-242(2013.04)学内技術認定制度
13. 杉本 公平,関 壽之,鴨下 桂子,飯倉 絵理,堀谷 まどか,上田 和,種元 智洋,斎藤 元章,拝野 貴之,林 博,和田 誠司,大浦 訓章,岡本 愛光. 医師の行う不妊外来カウンセリングの現状(原著論文) 日本受精着床学会雑誌(0914-6776)30 卷 1 号 Page136-140(2013.03)
14. Nakashima A, Yamanaka-Tatematsu M, Fujita N, Koizumi K, Shima T, Yoshida T, Nikaido T, Okamoto A, Yoshimori T, Saito S. Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia. Autophagy. 2013 Mar 1;9(3):303-16.
15. Yanagida S, Taniue K, Sugimasa H, Nasu E, Takeda Y, Kobayashi M, Yamamoto T, Okamoto A, Akiyama T. ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma. Sci Rep. 2013 Feb 19;3:1305.
16. 白石 絵莉子,山本 瑠伊,山下 修位,林 千景,駒崎 裕美,高橋 一彰,堀谷 まどか,永田 知映,上田 和,斎藤 元章,矢内原 臨,高倉 聡,山田 恭輔,落合 和徳,岡本 愛光. 卵巣原発ミューラー管性腺肉腫の1例 妊孕性温存手術後の再発(原著論文/症例報告) 東京産科婦人科学会会誌(2186-0599)62 卷 1 号 Page116-121(2013.01)
17. 佐藤佳世, 高倉聡, 岡本愛光. 【婦人科がん手術の最前線】卵巣がん 卵巣がんに対する staging laparotomy (解説/特集) 産婦人科の実際(0558-4728)62 卷 1 号 Page59-66(2013.01)
18. Kunito S, Takakura S, Nagata C, Saito M, Yanaihara N, Yamada K, Okamoto A, Sasaki H, Ochiai K, Tanaka T. Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line

- chemotherapy. J Obstet Gynaecol Res. 2012 Dec;38(12):1367-75.
19. 鴨下 桂子,高野 浩邦,平井 利明,松井 仁志,田沼 有希子,佐藤 佳世,森本 恵爾,江澤 正浩,小曾根 浩一,飯田 泰志,青木 宏明,田部 宏,栗田 正,谷口 洋,佐々木 寛,岡本 愛光. 【卵巣成熟嚢胞性奇形腫】 卵巣成熟嚢胞性奇形腫を合併した抗 NMDAR 抗体陽性脳炎の 1 例(原著論文/特集) 関東連合産科婦人科学会誌(2186-0610)49 巻 4 号 Page675-678(2012.11)
20. 佐藤 泰輔,種元 智洋,松岡 知奈,松井 仁志,梶原 一紘,堀谷 まどか,土橋 麻美子,田中 邦治,和田 誠司,大浦 訓章,恩田 威一,岡本 愛光. 羊水過多をきたした胎盤血管腫の 2 例(原著論文) 東京産科婦人科学会誌(2186-0599)61 巻 3 号 Page408-412(2012.10)
21. 飯田 泰志(東京慈恵会医科大学産婦人科講座),小田 瑞恵,岡本 愛光. 【産婦人科の薬剤使用プラクティス:病態別処方-婦人科編】 感染症 尖圭コンジローマ(解説/特集) 産婦人科の実際(0558-4728)61 巻 11 号 Page1580-1583(2012.10)
22. 森川 あすか,高倉 聡,岡本 愛光. 【産婦人科医療の未来の予測】 卵巣がんの発見と治療(解説/特集) 産婦人科の実際(0558-4728)61 巻 10 号 Page1435-1442(2012.10)
23. 杉本 公平,野口 幸子,鴨下 桂子,伊藤 由紀,横須賀 治子,飯倉 絵理,斎藤 幸代,川口 里恵,上田 和,拝野 貴之,斎藤 元章,林 博,高倉 聡,大浦 訓章,岡本 愛光,田中 忠夫. 挙児希望患者に対する鏡視下手術後転帰についての検討(原著論文) 日本産科婦人科内視鏡学会雑誌(1884-9938)28 巻 1 号 Page471-475(2012.08)
24. 平田 幸広(東京慈恵会医科大学産婦人科),矢内原 臨,落合 和徳,岡本 愛光. 【婦人科がんの最新医学】 (PART.4)卵巣がんの最新医学 卵巣がんの再発パターン別治療方針(解説/特集) からだの科学(0453-3038)274 号 Page139-142(2012.08)
25. 坂本 優(佐々木研究所附属杏雲堂病院 婦人科),嘉屋 隆介,三宅 清彦,小屋松 安子,茂木 真,秋谷 司,落合 和徳,栗津 邦男,田中 忠夫,岡本 愛光. 【産婦人科領域レーザー診療の現状と将来】 子宮頸部初期癌ならびに異形成に対する光線力学療法(総説/特集) 日本レーザー医学会誌(0288-6200)33 巻 2 号 Page117-121(2012.08)
26. 三宅 清彦(佐々木研究所附属杏雲堂病院 婦人科),嘉屋 隆介,小屋松 安子,茂木 真,秋谷 司,田中 忠夫,坂本 優,岡本 愛光. 【産婦人科領域レーザー診療の現状と将来】 子宮頸部再発病変に対する光線力学療法(PDT)の現状と展望(総説/特集) 日本レーザー医学会誌(0288-6200)33 巻 2 号

- Page136-140(2012.08)
27. 大浦 訓章(東京慈恵会医科大学産婦人科),塚原 麻帆,松岡 知奈,佐藤 泰輔,梶原 一紘,佐藤 陽一,加藤 淳子,土橋 麻美子,田中 邦治,川口 里恵,種元 智洋,岡本 愛光.【産科外来診療フローチャート-妊婦管理のすべて-】リスク因子の抽出と評価(解説/特集) 産婦人科の実際(0558-4728)61 巻 7 号 Page959-964(2012.07)
 28. 岡本愛光,田部宏,落合和徳,田中忠夫. 卵巣癌の最近の臨床試験の動向について—GCIIG 会議より産科と婦人科 別刷 79 巻 6 号 Page767-773 (2012.06)
 29. 寒河江 悟(JR 札幌病院 産婦人科),青木 大輔,進 伸幸,岡本 愛光,青谷 恵利子,竹内 正弘,万代 昌紀, JGOG・GCIIG 委員会.【婦人科がん-最新の研究動向-】婦人科がん 概論 国際共同研究の動向 Gynecologic Cancer Intergroup(GCIIG)での議論を中心に(解説/特集) 日本臨床(0047-1852)70 巻増刊 4 婦人科がん Page59-66(2012.06)
 30. 矢内原 臨(東京慈恵会医科大学産婦人科),岡本 愛光,落合 和徳,田中 忠夫.【婦人科がん-最新の研究動向-】卵巣がん 卵巣癌の発癌機構 分子機構(解説/特集) 日本臨床(0047-1852)70 巻増刊 4 婦人科がん Page475-479(2012.06)
 31. Yanaihara N, Anglesio MS, Ochiai K, Hirata Y, Saito M, Nagata C, Iida Y, Takakura S, Yamada K, Tanaka T, Okamoto A. Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol. 2012 Sep;41(3):1094-100. Epub 2012 Jun 26.
 32. Ueda K, Yamada K, Kiyokawa T, Iida Y, Nagata C, Hamada T, Saito M, Aoki K, Yanaihara N, Takakura S, Okamoto A, Ochiai K, Ohkawa K, Tanaka T. Pilot study of CD147 protein expression in epithelial ovarian cancer using monoclonal antibody 12C3. J Obstet Gynaecol Res. 2012 Sep;38(9):1211-9. Epub 2012 May 8.
 33. 山口 乃里子,高倉 聡,關 壽之,嘉屋 隆介,永田 知映,国東 志郎,斉藤 元章,矢内原 臨,山田 恭輔,岡本 愛光,落合 和徳,田中 忠夫. 術前診断に難渋した後腹膜神経鞘腫の 1 例(原著論文/症例報告) 東京産科婦人科学会会誌(2186-0599)61 巻 1 号 Page123-126(2012.04)
 34. Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T, Ohkawa K. Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol. 2012 Jun;40(6):2122-30. Epub 2012 Mar 19.
 35. Nagata C, Yanagida S, Okamoto A, Morikawa A, Sugimoto K, Jikei Gynecology Staffs, et al. Risk

factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. *J Obstet Gynaecol Res.* 2012 Apr;38(4):639-44. Epub 2012 Mar 13.

(研究分担者:高野忠夫)

1. Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Tamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzazana D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A. Gynecologic Cancer InterGroup (GCIg) Consensus Review for Clear Cell Carcinoma of the Ovary. *Int J Gynecol Cancer.* 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289. PMID: 25341576 [PubMed - in process]
2. Tokunaga H, Watanabe Y, Niikura H, Nagase S, Toyoshima M, Shiro R, Yokoyama Y, Mizunuma H, Ohta T, Nishiyama H, Watanabe T, Sato N, Sugiyama T, Takano T, Takahashi F, Yaegashi N. Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit. *Int J Clin Oncol.* 2014 Nov 14. [Epub ahead of print]
3. Matsumoto K, Katsumata N, Shibata T, Satoh T, Saitou M, Yunokawa M, Takano T, Nakamura K, Kamura T, Konishi I. Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503). *Gynecol Oncol.* 2014 Oct 31. pii: S0090-8258(14)01410-3. doi: 10.1016/j.ygyno.2014.10.026.
4. Otsuki A, Otsuki T, Tokunaga H, Niikura H, Nagase S, Sugiyama T, Toyoshima M, Utsunomiya H, Yokoyama Y, Mizunuma H, Sato N, Terada Y, Shoji T, Sugiyama T, Nakahara K, Ohta T, Yamada H, Tase T, Nishiyama H, Fujimori K, Takano T, Takahashi F, Watanabe Y, Yaegashi N. Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit. *Int J Clin Oncol.* 2014 Jul 18.
5. Matsuo K, Cahoon SS, Gualtieri M, Scannell CA, Jung CE, Takano T, Paulson RJ, Muderspach LI, Roman LD. Significance of Adenomyosis on Tumor Progression and Survival Outcome of Endometrial Cancer. *Ann Surg Oncol.* 2014 Jul 8.
6. Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H, Kaiho M, Otsuki T, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sugiyama

- T. A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). *Cancer Chemother Pharmacol.* 2014 Mar 1.
7. Takano T, Otsuki T, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Niikura H, Ito K, Yaegashi N, Yamada H, Tase T, Kagabu M, Shoji T, Sugiyama T, Sato N, Fujimoto T, Terada Y, Nakahara K, Kurachi H, Yokoyama Y, Mizunuma H, Soeda S, Nishiyama H, Matsumoto T, Sato S, Shimada M, Kigawa J. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study. *Int J Clin Oncol.* 2014 Jan 7.
 8. Yokoyama Y, Futagami M, Watanabe J, Sato N, Terada Y, Miura F, Sugiyama T, Takano T, Yaegashi N, Kojimahara T, Kurachi H, Nishiyama H, Fujimori K, Tase T, Mizunuma H. Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. *Mol Clin Oncol.* 2014 Mar;2(2):212-218. Epub 2013 Dec 10.
 9. Suzuki F, Nagase S, Suzuki K, Oba E, Hiroki E, Matsuda Y, Akahira J, Nishigori H, Sugiyama T, Otsuki T, Yoshinaga K, Takano T, Niikura H, Ito K, Sasano H, Yaegashi N. Decreased expression of 14-3-3 σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma. *Tohoku J Exp Med.* 2013;231(3):193-9.
 10. Niikura H, Kaiho-Sakuma M, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Takano T, Watanabe M, Ito K, Yaegashi N. Tracer injection sites and combinations for sentinel lymph node detection in patients with endometrial cancer. *Gynecol Oncol.* 2013 Nov;131(2):299-303.
 11. Takano T, Niikura H, Ito K, Nagase S, Utsunomiya H, Otsuki T, Toyoshima M, Tokunaga H, Kaiho-Sakuma M, Shiga N, Nagai T, Tanaka S, Otsuki A, Kurosawa H, Shigeta S, Tsuji K, Yamaguchi T, Yaegashi N. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. *Int J Clin Oncol.* 2013 Oct 24.
 12. Kojimahara T, Nakahara K, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sato N, Terada Y, Tase T, Yokoyama Y, Mizunuma H, Shoji T, Sugiyama T, Kurachi H. Yolk sac tumor of the ovary: a retrospective

- multicenter study of 33 Japanese women by Tohoku Gynecologic Cancer Unit (TGCU). *Tohoku J Exp Med.* 2013;230(4):211-7.
13. Shoji T, Kumagai S, Yoshizaki A, Yokoyama Y, Fujimoto T, Takano T, Yaegashi N, Nakahara K, Nishiyama H, Sugiyama T.: Efficacy of neoadjuvant chemotherapy followed by radical hysterectomy in locally advanced non-squamous carcinoma of the uterine cervix: a retrospective multicenter study of Tohoku Gynecologic Cancer Unit. *Eur J Gynaecol Oncol.* 2012;33(4):353-7.
 14. Nagai T, Niikura H, Kurosawa H, Tanaka S, Otsuki T, Utunomiya H, Nagase S, Takano T, Ito K, Kaiho Y, Nakagawa H, Arai Y, Yaegashi N.: Individualized radical hysterectomy procedure using intraoperative electrical stimulation for patients with cervical cancer. *Int J Gynecol Cancer.* 2012 Nov;22(9):1591-6.
 15. Niikura H, Okamoto S, Otsuki T, Yoshinaga K, Utunomiya H, Nagase S, Takano T, Ito K, Watanabe M, Yaegashi N.: Prospective study of sentinel lymph node biopsy without further pelvic lymphadenectomy in patients with sentinel lymph node-negative cervical cancer. *Int J Gynecol Cancer.* 2012 Sep;22(7):1244-50.
- (研究分担者：杉山 徹)
1. Hideki Tokunaga, Yoh Watanabe, Hitoshi Niikura, Satoru Nagase, Masafumi Toyoshima, Reiji Shiro, Yoshihito Yokoyama, Hideki Mizunuma, Tsuyoshi Ohta, Hiroshi Nishiyama, Takafumi Watanabe, Naoto Sato, Toru Sugiyama, Tadao Takano, Fumiaki Takahashi, Nobuo Yaegashi. Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit. *International Journal of Clinical Oncology.* Published online.12/2014;
 2. Rie Oyama, Chizuko Isurugi, Shino Tanaka, Tomoyuki Fukagawa, Ikue Nakayama, Yuri Sasaki, Tomonobu Kanasugi, Aikihiko Kikuchi, Toru Sugiyama The new approach to diagnosis and evaluate of placenta accrete using 3D slicer. *Placenta.*2014; 35(10):A10–A11
 3. Ai Otsuki, Takeo Otsuki, Hideki Tokunaga, Hitoshi Niikura, Satoru Nagase, Takashi Sugiyama, Masafumi Toyoshima, Hiroki Utunomiya, Yoshihito Yokoyama, Hideki Mizunuma, , Kenji Nakahara, Tsuyoshi Ohta, Hidekazu Yamada, Toru Tase, Hiroshi Nishiyama, Keiya Fujimori, Tadao

- Takano, Fumiaki Takahashi, Yoh Watanabe, Nobuo Yaegashi. Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit. Published online.7/2014
4. Tadahiro Shoji, Eriko Takatori, Yuki Miura, Anna Takada, Hideo Omi, Masahiro Kagabu, Tatsuya Honda, Fumiharu Miura, Satoshi Takeuchi, Toru Sugiyama Pilot Study of Intraperitoneal Administration of Triamcinolone Acetonide for Cancerous Ascites in Patients With End-Stage Gynecological Cancer. *International Journal of Gynecological Cancer*. 2014; 24(6):1093-1097.
 5. Tadahiro Shoji, Eriko Takatori, Yoshitaka Kaido, Hideo Omi, Yoshihito Yokoyama, Hideki Mizunuma, Michiko Kaiho, Takeo Otsuki, Tadao Takano, Nobuo Yaegashi, Hiroshi Nishiyama, Keiya Fujimori, Toru Sugiyama. A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). *Cancer Chemotherapy and Pharmacology* . 2014;73(5):895-901.
 6. Eriko Takatori, Tadahiro Shoji, Yuki Miura, Satoshi Takeuchi, Akira Yoshizaki, Toru Sugiyama. Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy. *The journal of obstetrics and gynaecology research*.39(8)1354-1358.2013
 7. Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa. Loss of HOXD10 expression induced by upregulation of miR-10b accelerates the migration and invasion activities of ovarian cancer cells. *International journal of oncology* . 43 (1) 63-71.2013
 8. Miyuki Terata, Akihiko Kikuchi, Tomonobu Kanasugi, Rie Oyama, Akimune Fukushima, Toru Sugiyama. Prenatal diagnosis of parasitic conjoined twins with three-dimensional ultrasound. *Congenital Anomalies* . 131-133.2013
 9. Yoshihito Yokoyama, Masayuki Futagami, Toshio Fujimoto, Yukihiro Terada, Eriko Takatori, Toru Sugiyama, Takeo Otsuki, Nobuo Yaegashi, Takanobu Kojimahara, Hirohisa Kurachi, Hiroshi Nishiyama, Keiya Fujimori,

- Toru Tase, Hideki Mizunuma. Investigation of the clinicopathological features of fallopian tube malignancy. *Oncology Reports*.30.79-84.2013
10. Yasuo Ohashi, Yukari Uemura, Yasuhito Fujisaka, Toru Sugiyama, Hironobu Ohmatsu, Noriyuki Katsumata, Rumiko Okamoto, Nagahiro Saijo, Tomomitsu Hotta Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. *Cancer Science*.;104(4):481-485.2013
 11. Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, Fumiaki Takahashi, Hirofumi Michimae, Eizo Kimura, Daisuke Aoki, Toshiko Jobo, Shoji Kodama, Fumitoshi Terauchi, Toru Sugiyama, Kazunori Ochiai, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. *The Lancet Oncology* Vol. 14(10) 1020-1026.2013
 12. Kimio Ushijima, Toshiharu Kamura, Kazuo Tamura, Kazuo Kuzuya, Toru Sugiyama, Kiichiro Noda, Kazunori Ochiai. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. *International Journal of Clinical Oncology*. 18 (1) 126-131 .2013
 13. Eriko Takatori, Tadahiro Shoji, Takashi Sawai, Akira Kurose, Toru Sugiyama. Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γ H2AX. *OncoTargets and Therapy*; 6:901-7. 2013
 14. Tomonobu Kanasugi, Akihiko Kikuchi, Atsushi Matsumoto, Miyuki Terata, Chizuko Isurugi, Rie Oyama, Akimune Fukushima, Toru Sugiyama. Monochorionic twin fetus with VACTERL association after intracytoplasmic sperm injection. *Congenital Anomalies*; 53(2):95-7.2013
 15. Rie Oyama, Marianna Jakab, Miuki Terata, Chizuko Isurugi, Yoshitaka Kaido, Tomonobu Knasugi, Akihiko Kikuchi, Toru Sugiyama, Ron Kikinis, Sonia Pujol. Towards improved ultrasound-based analysis and 3D visualization of the fetal brain using 3D Slicer. *Ultrasound in Obstetrics*

- and Gynecology.04/2013;
16. Yoshihito Yokoyama, Masayuki Futagami, Toshio Fujimoto, Yukihiro Terada, Eriko Takatori, Toru Sugiyama, Takeo Otsuki, Nobuo Yaegashi, Takanobu Kojimahara, Hirohisa Kurachi, Hiroshi Nishiyama, Keiya Fujimori, Toru Tase, Hideki Mizunuma. Investigation of the clinicopathological features of fallopian tube malignancy. *Oncology Reports* 04/2013;
 17. Eriko Takatori, Tadahiro Shoji, Yasuko Suga, Hanae Niinuma, Yuki Miura, Yoshitaka Kaido, Anna Takada, Masahiro Kagabu, Satoshi Takeuchi, Toru Sugiyama .A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcinoma of the uterine cervix. *International Journal of Clinical Oncology*.03/2013;
 18. Miyuki Terata, Akihiko Kikuchi, Tomonobu Kanasugi, Rie Oyama, Akimune Fukushima, Toru Sugiyama. Prenatal diagnosis of parasitic conjoined twins with three-dimensional ultrasound. *Congenital Anomalies* 09/2013;:131-3.2013
 19. Tadahiro Shoji, Eriko Takatori, Tatsunori Saito, Hideo Omi, Masahiro Kagabu, Fumiharu Miura, Satoshi Takeuchi, Toru Sugiyama. Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix. *Cancer Chemotherapy and Pharmacology*:12/ 2012
 20. Toru Sugiyama. Second-Line Chemotherapy for Platinum- and Taxane-Resistant Epithelial Ovarian Cancer: Pegylated Liposomal Doxorubicin (PLD), Irinotecan, and Combination Therapies at Lower Doses . 02/2012
 21. Eriko Takatori, Tadahiro Shoji, Jiyu Miura, Satoshi Takeuchi, Akira Yoshizaki, Toru Sugiyama. Case of peptide-YY-producing strumal carcinoid of the ovary: A case report and review. *Journal of Obstetrics and Gynaecology Research*; 38(10):1266-70. 2012
 22. Satoshi Yamaguchi, Ryuichiro Nishimura, Nobuo Yaegashi, Kazushige Kiguchi, Toru Sugiyama, Tsunekazu Kita, Kaneyuki Kubushiro, Katsuji Kokawa, Masamichi Hiura, Katsumi Mizutani, Kaichiro Yamamoto, Ken Takizawa. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic

- Oncology Group study (JGOG 1065). *Oncology Reports*; 28(2):487-93. 2012
23. Masashi Takano, Hiroshi Tsuda, Toru Sugiyama. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment? *Journal of Experimental & Clinical Cancer Research*; 31:53. 2012
 24. Yoshitaka Kaido, Akihiko Kikuchi, Tomonobu Kanasugi, Akimune Fukushima, Toru Sugiyama. Acute abdomen due to ovarian congestion: A fallopian tube accompanied by a paratubal cyst, coiling tightly round the ovary. *Journal of Obstetrics and Gynaecology Research* 06/2012
 25. Akimune Fukushima, Atsushi Matsumoto, Miyuki Terata, Tomonobu Kanasugi, Kenji Nakai. Prenatal diagnosis of fetal arrhythmias and assesment of autonomic nervous system activity by fetal magnetocardiography. *The Open Medical Devices Journal*.4;13-21.2012
 26. Tadahiro Shoji, Seisuke Kumagai, Akira Yoshizaki, Yoshihito Yokoyama, Toshiro Fujimoto, Tadao Takano, Npbuo Yaegashi, Kenji Nakahara, Hiroshi Nishiyama, Toru Sugiyama. Efficacy of neoadjuvant chemotherapy followed by radical hysterectomy in locally advanced non-squamous carcinoma of the uterine cervix: a retrospective multicenter study of Tohoku Gynecologic Cancer Unit. *European journal of gynaecological oncology*. 33(4):353-7. 2012
 27. Murai M, Takatori E, Omi H, Isurugi C, Honda T, Kumagai S, Shoji T, Oyama R, Yoshisaki. A, Sugiyama T . Anti-Müllerian hormone and 3D-power Doppler histogram: markers of ovarian function with in vitro fertilization treatment *Reproductive Medicine and Biology*; 9(3):151-161,2012
 28. Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study. *Experimental and therapeutic medicine*; 3(1):60-65,2012
 29. Yamamoto S, Tsuda H, Shimazaki H, Takano M, Yoshikawa T, Kuzuya K, Tsuda H, Kurachi H, Kigawa H, Kikuchi Y, Sugiyama T, Matsubara O. Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture.. *International journal*

- of gynecological pathology: official journal of the International Society of Gynecological Pathologists; 31(2):116-24,2012
30. Shoji T, Takatori E, Oyama R, Kumagai S, Fukushima A, Yoshizaki A, Sugiyama T. Tako-Tsubo Cardiomyopathy Caused Immediately following Cesarean Section Delivery of Triplets: A Case Report. *Gynecologic and Obstetric Investigation*;74(1):84-8, 2012
 31. Takano M, Tsuda H, Sugiyama T. Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment? *Journal of Experimental & Clinical Cancer Research.*; 31:53, 2012
 32. Takatori E, Shoji T, Kumagai S, Sawai T, Kurose A, Sugiyama T. Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γ H2AX induced by anticancer agents. *Journal of Ovarian Research*; 5(1):16,2012
 33. Shibazaki M, Maesawa C, Akasaka K, Kasai S, Yasuhira S, Kanno K, Nakayama I, Sugiyama T, Wakabayashi G, Masuda T, Mori N. Transcriptional and post-transcriptional regulation of β III-tubulin protein expression in relation with cell cycle-dependent regulation of tumor cells. *International journal of oncology (Int J Oncol)* Vol. 40 (3). 695-702,2012
- (研究分担者:野河孝充)
1. Okadome M, Saito T, Tanaka H, Nogawa T, Furuta R, Watanabe K, Kita T, Yamamoto K, Mikami M, Takizawa K; Japanese Gynecologic Oncology Group (JGOG): Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2. *J Obstet Gynaecol Res* 2014; 40(2):561-569.
 2. 野河孝充: 卵巣がん-標準治療と先進医療 【先進医療】再発卵巣がん・卵管がんに対する化学療法-パクリタキセル静脈内投与、カルボプラチン静脈内投与およびベバシズマブ静脈内投与の併用療法、ならびにベバシズマブ静脈内投与による維持療法. *ライフライン 21 がんの先進医療* 2014 年, 通巻 12 号, pp37-40.
 3. 友野勝幸、小島淳美、香川昭博、佐伯健二、大亀真一、白山裕子、寺本典弘、野河孝充: 集団検診で発見された子宮頸部“胃型”粘液性腺癌の 1 例. *日本臨床細胞学会雑誌* 2014 年, 第 53 巻第 2 号, pp104-108, 公益社団法人日本臨床細胞学会.
 4. 竹原和宏、白山裕子、野河孝充: IV. その他 A. 外陰癌・陰癌 Q2 リンパ節廓清が必要な症例と必要な範囲について教えてください. *婦人科癌診療 Q&A 一つ上を行く診療の実践* 2014 年, pp.275-279.
 5. 野河孝充、竹原和宏、白山裕子: